E-Newsletter - November 2015

New Study Chair Appointments | Alliance A071101

The Alliance for Clinical Trials in Oncology has appointed two new study co-chairs to an Alliance trial - Alliance A071101: A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, Alliance IND #15380) Vaccine Given with Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM). The new co-chairs are Ian F. Parney, MD, PhD, Mayo Clinic, and Orin Bloch, MD, Northwestern University Feinberg School of Medicine.

The successful completion of this study is very important to the Alliance, especially in light of the data presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting for HSPPC-96 in newly diagnosed glioblastoma (J Clin Oncol 33, 2015 (suppl; abstr 2011). These data conclude that vaccination with autologous tumor-derived heat shock proteins improves survival compared to standard therapy for newly diagnosed GBM. Systemic immunosuppression driven by peripheral monocyte expression of PD-L1 is a previously unidentified factor that may mitigate vaccine efficacy.


*  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *

For other articles in the November issue of the Alliance E-News newsletter, see below.